Chronic Fatigue Syndrome and Herpesvirus Infection

  • Kazuhiro Kondo


Chronic fatigue syndrome (CFS) is a disease of unknown etiology which is accompanied by severe fatigue as a main complaint. The prominence of the acute onset of illness, the persistent symptoms consistent with a viral infection, and the increased titers of viral antibodies and enhanced activity of the interferon-induced enzyme suggest the role of viruses in CFS. In other words, in CFS patients, it is suggested that there may be some kind of “postinfectious fatigue syndrome” following any infection by a virus. Among the variety of viruses evaluated to date are enteroviruses, retroviruses, and human herpesviruses.

CFS is a disease which lasts far longer than postinfectious fatigue. It is considered, accordingly, that the infection causing CFS is a latent infection with some herpesvirus. Human herpesvirus 6 (HHV-6) has exhibited the most promise as a candidate for a CFS-associated virus. As there may be an unusual latent infection with HHV-6, which may be an etiology of CFS in CFS patients, a study of latent infection is considered to be important in understanding CFS.


Chronic Fatigue Syndrome Latent Infection Hemorrhagic Fever With Renal Syndrome Chronic Fatigue Syndrome Patient Postviral Fatigue Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pedersen TH, Nielsen OB, Lamb GD, Stephenson DG (2004) Intracellular acidosis enhances the excitability of working muscle. Science 305:1144–1147PubMedCrossRefGoogle Scholar
  2. 2.
    Katafuchi T, Kondo T, Yasaka T, Kubo K, Take S, Yoshimura M (2003) Prolonged effects of polyriboinosinic:polyribocytidylic acid on spontaneous running wheel activity and brain interferon-alpha mRNA in rats: a model for immunologically induced fatigue. Neuroscience 120:837–845PubMedCrossRefGoogle Scholar
  3. 3.
    Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguarnera M (2003) L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology 35:94–97CrossRefGoogle Scholar
  4. 4.
    Schwartz AL, Thompson JA, Masood N (2002) Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 26 Spec No. 2: E85–E90CrossRefGoogle Scholar
  5. 5.
    Arai M, Yamazaki H, Inoue K, Fushiki T (2001) Effects of intracranial injection of transforming growth factor-beta relevant to central fatigue on the waking electroencephalogram of rats: comparison with effects of exercise. Prog Neuropsychopharmacol Biol Psychiatr 8:307–312Google Scholar
  6. 6.
    Tomoda A, Joudoi T, Rabab e-M, Matsumoto T, Park TH, Miike T (2005) Cytokine production and modulation: comparison of patients with chronic fatigue syndrome and normal controls. Psychiatr Res 288:101–104CrossRefGoogle Scholar
  7. 7.
    Buchwald D, Cheney PR, Peterson DL, Henry B, Wormsley SB, Geiger A, Ablashi DV, Salahuddin SZ, Saxinger C, Biddle R, Kiknus, R, Jolesz FA, Folks T, Balachandran N, Peter JB, Gallo RC, Komaroff AL (1992) A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection. Ann Intern Med 116:103–113PubMedGoogle Scholar
  8. 8.
    Levine PH, Jacobson S, Pocinki AG, Cheney P, Peterson D, Connelly RR, Weil R, Robinson SM, Ablashi DV, Salahuddin SZ, Pearson GR, Hoover R (1992) Clinical, epidemiologic, and virologic studies in four clusters of the chronic fatigue syndrome. Arch Intern Med 152:1611–1616PubMedCrossRefGoogle Scholar
  9. 9.
    Morin SF, Charles KA, Malyon AK (1984) The psychological impact of AIDS on gay men. Am Psychol 39:1288–1293PubMedCrossRefGoogle Scholar
  10. 10.
    Ayres JG, Flint N, Smith EG, Tunnicliffe WS, Fletcher TJ, Hammond K, Ward D, Marmion BP (1998) Post-infection fatigue syndrome following Q fever. QJM 91:105–123PubMedCrossRefGoogle Scholar
  11. 11.
    Hatchette TF, Hayes M, Merry H, Schlech WF, Marrie TJ (2003) The effect of C. burnetii infection on the quality of life of patients following an outbreak of Q fever. Epidemiol Infect 4:491–495Google Scholar
  12. 12.
    Horwitz CA, Henle W, Henle G, Schmitz H (1975) Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. Am J Med 58:330–338PubMedCrossRefGoogle Scholar
  13. 13.
    Buchwald D, Goldenberg DL, Sullivan JL, Komaroff AL (1987) The “chronic, active Epstein-Barr virus infection” syndrome and primary fibromyalgia. Arthritis Rheum 30:1132–1136PubMedCrossRefGoogle Scholar
  14. 14.
    Hotchin NA, Read R, Smith DG, Crawford DH (1989) Active Epstein-Barr virus infection in post-viral fatigue syndrome. J Infect 18:143–150PubMedCrossRefGoogle Scholar
  15. 15.
    Soto NE, Straus SE (2000) Chronic fatigue syndrome and herpesviruses: the fading evidence. Herpes 7:46–50PubMedGoogle Scholar
  16. 16.
    Swanink CM, van der Meer JW, Vercoulen JH, Bleijenberg G, Fennis JF, Galama JM (1994) Epstein-Barr virus (EBV) and the chronic fatigue syndrome: normal virus load in blood and normal immunologic reactivity in the EBV regression assay. Clin Infect Dis 19:1390–1392Google Scholar
  17. 17.
    Kimura H, Hoshino Y, Hara S, Sugaya N, Kawada J, Shibata Y, Kojima S, Nagasaka T, Kuzushima K, Morishima T (2005) Differences between T cell-type and natural killer celltype chronic active Epstein-Barr virus infection. J Infect Dis 191:531–539PubMedCrossRefGoogle Scholar
  18. 18.
    Barnes DM (1986) Mystery disease at Lake Tahoe challenges virologists and clinicians. Science 234:541–542PubMedCrossRefGoogle Scholar
  19. 19.
    Eisen SA, Kang HK, Murphy FM, Blanchard MS, Reda DJ, Henderson WG, Toomey R, Jackson LW, Alpern R, Parks BJ, Klimas N, Hall C, Pak HS, Hunter J, Karlinsky J, Battistone MJ, Lyons MJ (2005) Gulf War veterans’ health: medical evaluation of a US cohort. Ann Intern Med 142:881–890PubMedGoogle Scholar
  20. 20.
    Hotopf M, David AS, Hull L, Nikalaou V, Unwin C, Wessely S 2003.Gulf war illness: better, worse, or just the same? A cohort study. BMJ 183:1370CrossRefGoogle Scholar
  21. 21.
    Roffey R, Lantorp K, Tegnell A, Elgh F (2002) Biological weapons and bioterrorism preparedness: importance of public-health awareness and international cooperation. Clin Microbiol Infect 8:522–528PubMedCrossRefGoogle Scholar
  22. 22.
    Snell CR, Vanness JM, Strayer DR, Stevens SR (2002) Physical performance and prediction of 2-5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndrome. In Vivo 16:107–109PubMedGoogle Scholar
  23. 23.
    Morag A, Tobi M, Ravid Z, Revel M, Schattner A (1982) Increased (2′-5′)-oligo-A synthetase activity in patients with prolonged illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet 1:744PubMedCrossRefGoogle Scholar
  24. 24.
    Straus SE, Tosato G, Armstrong G, Lawley T, Preble OT, Henle W, Davey R, Pearson G, Epstein J, Brus I, Blaese RM (1985) Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 102:7–16PubMedGoogle Scholar
  25. 25.
    Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, Jones JF, Dubois RE, Cunningham-Rundles C, Pahwa S, Tosato G, Zegans LS, Purtilo DT, Browh N, Schooles RT, Brus I (1988) Chronic fatigue syndrome: a working case definition. Ann Intern Med 108:387–389PubMedGoogle Scholar
  26. 26.
    Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO (1985) Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated antiearly antigen antibodies. Ann Intern Med 102:1–7PubMedGoogle Scholar
  27. 27.
    Josephs SF, Henry B, Balachandran N, Strayer D, Peterson D, Komaroff AL, Ablashi DV (1991) HHV-6 reactivation in chronic fatigue syndrome. Lancet 337:1346–1347PubMedCrossRefGoogle Scholar
  28. 28.
    Archard LC, Bowles NE, Behan PO, Bell EJ, Doyle D (1988) Postviral fatigue syndrome: persistence of enterovirus RNA in muscle and elevated creatine kinase. J R Soc Med 81:326–329PubMedGoogle Scholar
  29. 29.
    Bell EJ, McCartney RA, Riding MH (1988) Coxsackie B viruses and myalgic encephalomyelitis. J R Soc Med 81:329–331PubMedGoogle Scholar
  30. 30.
    Calder BD, Warnock PJ, McCartney RA, Bell EJ (1987) Coxsackie B viruses and the postviral syndrome: a prospective study in general practice. J R Coll Gen Pract 37:11–14PubMedGoogle Scholar
  31. 31.
    Cunningham L, Bowles NE, Lane RJ, Dubowitz V, Archard LC (1990) Persistence of enteroviral RNA in chronic fatigue syndrome is associated with the abnormal production of equal amounts of positive and negative strands of enteroviral RNA. J Gen Virol 71:1399–1402PubMedCrossRefGoogle Scholar
  32. 32.
    Halpin D, Wessely S (1989) VP-1 antigen in chronic postviral fatigue syndrome. Lancet 1:1028–1029PubMedCrossRefGoogle Scholar
  33. 33.
    Yousef GE, Bell EJ, Mann GF, Murugesan V, Smith DG, McCartney RA, Mowbray JF (1988) Chronic enterovirus infection in patients with postviral fatigue syndrome. Lancet 1:146–150PubMedCrossRefGoogle Scholar
  34. 34.
    Khan AS, Heneine WM, Chapman LE, Gary Jr HE, Woods TC, Folks TM, Schonberger LB (1993) Assessment of a retrovirus sequence and other possible risk factors for the chronic fatigue syndrome in adults. Ann Intern Med 118:241–245PubMedGoogle Scholar
  35. 35.
    Jordan MC (1983) Latent infection and the elusive cytomegalovirus. Rev Infect Dis 5:205–215PubMedGoogle Scholar
  36. 36.
    Krueger GR, Wassermann K, De Clerck LS, Stevens WJ, Bourgeois N, Ablashi DV, Josephs SF, Balachandran N (1990) Latent herpesvirus-6 in salivary and bronchial glands [letter; comment]. Lancet 336:1255–1256PubMedCrossRefGoogle Scholar
  37. 37.
    Kondo K, Kondo T, Okuno T, Takahashi M, Yamanishi K (1991) Latent human herpesvirus 6 infection of human monocytes/macrophages. J Gen Virol 72:1401–1408PubMedCrossRefGoogle Scholar
  38. 38.
    Yasukawa M, Ohminami H, Sada E, Yakushijin Y, Kaneko M, Yanagisawa K, Kohno H, Bando S, Fujita S (1999) Latent infection and reactivation of human herpesvirus 6 in two novel myeloid cell lines. Blood 93:991–999PubMedGoogle Scholar
  39. 39.
    Luppi M, Barozzi P, Morris C, Maiorana A, Garber R, Bonacorsi G, Donelli A, Marasca R, Tabilio A, Torelli G (1999) Human herpesvirus 6 latently infects early bone marrow progenitors in vivo. J Virol 73:754–759PubMedGoogle Scholar
  40. 40.
    Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, Knott A, Dewhurst S, Insel RA, Epstein LG (1994) Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 331:432–438PubMedCrossRefGoogle Scholar
  41. 41.
    Kimberlin DW, Whitley RJ (1998) Human herpesvirus-6: neurologic implications of a newly described viral pathogen. J Neurovirol 4:474–485PubMedCrossRefGoogle Scholar
  42. 42.
    Kondo K, Nagafuji H, Hata A, Tomomori C, Yamanishi K (1993) Association of human herpesvirus 6 infection of the central nervous system with recurrence of febrile convulsions. J Infect Dis 167:1197–1200PubMedGoogle Scholar
  43. 43.
    Challoner PB, Smith KT, Parker JD, MacLeod DL, Coulter SN, Rose TM, Schultz ER, Bennett JL, Garber RL, Chang M, Schad PA, Stewart PM, Nowinski RC, Brown JP, Burmer GC (1995) Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci USA 92:7440–7444PubMedCrossRefGoogle Scholar
  44. 44.
    Sola P, Merelli E, Marasca R, Poggi M, Luppi M, Montorsi M, Torelli G (1993) Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction. J Neurol Neurosurg Psychiatry 56:917–919PubMedCrossRefGoogle Scholar
  45. 45.
    Caserta MT, Hall CB, Schnabel K, McIntyre K, Long C, Costanzo M, Dewhurst S, Insel R, Epstein LG (1994) Neuroinvasion and persistence of human herpesvirus 6 in children. J Infect Dis 170:1586–1589PubMedGoogle Scholar
  46. 46.
    Kondo K, Shimada K, Sashihara J, Tanaka-Taya K, Yamanishi K (2002) Identification of human herpesvirus 6 latency-associated transcripts. J Virol 76:4145–4151PubMedCrossRefGoogle Scholar
  47. 47.
    Mirandola P, Menegazzi P, Merighi S, Ravaioli T, Cassai E, Di Luca D (1998) Temporal mapping of transcripts in herpesvirus 6 variants. J Virol 72:3837–3844PubMedGoogle Scholar
  48. 48.
    Schiewe U, Neipel F, Schreiner D, Fleckenstein B (1994) Structure and transcription of an immediate-early region in the human herpesvirus 6 genome. J Virol 68:2978–2985PubMedGoogle Scholar
  49. 49.
    Kondo K, Mocarski ES (1995) Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Scand J Infect Dis Suppl 99:63–67PubMedGoogle Scholar
  50. 50.
    Kondo K, Xu J, Mocarski ES (1996) Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci USA 93:11137–11142PubMedCrossRefGoogle Scholar
  51. 51.
    Kempf W, Adams V, Wey N, Moos R, Schmid M, Avitabile E, Campadelli-Fiume G (1997) CD68+ cells of monocyte/macrophage lineage in the environment of AIDS-associated and classic-sporadic Kaposi sarcoma are singly or doubly infected with human herpesviruses 7 and 6B. Proc Natl Acad Sci USA 94:7600–7605PubMedCrossRefGoogle Scholar
  52. 52.
    Kondo K, Kaneshima H, Mocarski ES (1994) Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 91:11879–11883PubMedCrossRefGoogle Scholar
  53. 53.
    Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH (1991) Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 72:2059–2064PubMedCrossRefGoogle Scholar
  54. 54.
    Lerner AM, Dworkin HJ, Sayyed T, Chang CH, Fitzgerald JT, Beqaj S, Deeter RG, Goldstein J, Gottipolu P, O’Neill W (2004) Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-Barr virus and/or cytomegalovirus in patients with chronic fatigue syndrome. In Vivo 18:417–424PubMedGoogle Scholar
  55. 55.
    Kondo K, Sashihara J, Shimada K, Takemoto M, Amo K, Miyagawa H, Yamanishi K (2003) Recognition of a novel stage of beta-herpesvirus latency in human herpesvirus 6. J Virol 77:2258–2264PubMedCrossRefGoogle Scholar
  56. 56.
    Hummel M, Zhang Z, Yan S, DePlaen I, Golia P, Varghese T, Thomas G, Abecassis MI (2001) Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J Virol 75:4814–4822PubMedCrossRefGoogle Scholar
  57. 57.
    Soderberg-Naucler C, Streblow DN, Fish KN, Allan-Yorke J, Smith PP, Nelson JA (2001) Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiationdependent. J Virol 75:7543–7554PubMedCrossRefGoogle Scholar
  58. 58.
    Hoffmann B, Valerius O, Andermann M, Braus GH (2001) Transcriptional autoregulation and inhibition of mRNA translation of amino acid regulator gene cpcA of filamentous fungus Aspergillus nidulans. Mol Biol Cell 12:2846–2857PubMedGoogle Scholar
  59. 59.
    Nomura A, Iwasaki Y, Saito M, Aoki Y, Yamamori E, Ozaki N, Tachikawa K, Mutsuga N, Morishita M, Yoshida M, Asai M, Oiso Y, Saito H (2001) Involvement of upstream open reading frames in regulation of rat V(1b) vasopressin receptor expression. Am J Physiol Endocrinol Metab 280:E780–E787PubMedGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Kazuhiro Kondo
    • 1
  1. 1.Department of VirologyThe Jikei University School of MedicineTokyoJapan

Personalised recommendations